Key Points
- IDEXX EVP Nimrata Hunt sold shares: She sold 1,758 shares on March 3 at $634.57 (~$1.12M) and had sold 2,693 shares on Feb 26 at $661.54 (~$1.78M), cutting her stake by 8.83% to 18,141 shares (worth about $11.5M).
- Results and outlook: IDEXX reported Q EPS of $2.92 (missed by $0.01) and revenue of $1.09B (up 14.3% y/y and above estimates), set FY2026 EPS guidance of $14.29–$14.80, and carries a consensus analyst rating of "Moderate Buy" with a $783.33 price target.
IDEXX Laboratories, Inc. (NASDAQ:IDXX - Get Free Report) EVP Nimrata Hunt sold 1,758 shares of the firm's stock in a transaction dated Tuesday, March 3rd. The shares were sold at an average price of $634.57, for a total value of $1,115,574.06. Following the sale, the executive vice president owned 18,141 shares in the company, valued at approximately $11,511,734.37. The trade was a 8.83% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.
Nimrata Hunt also recently made the following trade(s):
- On Thursday, February 26th, Nimrata Hunt sold 2,693 shares of IDEXX Laboratories stock. The shares were sold at an average price of $661.54, for a total transaction of $1,781,527.22.
IDEXX Laboratories Stock Performance
NASDAQ IDXX traded down $7.92 during trading hours on Friday, reaching $611.00. The company's stock had a trading volume of 118,092 shares, compared to its average volume of 507,435. The stock has a market cap of $48.65 billion, a PE ratio of 46.75, a PEG ratio of 3.94 and a beta of 1.66. The business has a 50-day simple moving average of $668.54 and a 200 day simple moving average of $668.40. IDEXX Laboratories, Inc. has a 52 week low of $356.14 and a 52 week high of $769.98. The company has a current ratio of 1.23, a quick ratio of 0.90 and a debt-to-equity ratio of 0.23.
IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last released its earnings results on Monday, February 2nd. The company reported $2.92 earnings per share for the quarter, missing analysts' consensus estimates of $2.93 by ($0.01). The firm had revenue of $1.09 billion during the quarter, compared to analyst estimates of $1.07 billion. IDEXX Laboratories had a return on equity of 69.78% and a net margin of 24.62%.The business's revenue for the quarter was up 14.3% on a year-over-year basis. During the same quarter last year, the company earned $2.53 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. Equities research analysts predict that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.
Institutional Investors Weigh In On IDEXX Laboratories
Several large investors have recently modified their holdings of the stock. SHP Wealth Management purchased a new position in IDEXX Laboratories during the 4th quarter valued at about $26,000. Reflection Asset Management purchased a new stake in IDEXX Laboratories during the 4th quarter valued at $53,000. BDFS Capital LLC bought a new position in shares of IDEXX Laboratories during the fourth quarter valued at approximately $671,000. MidFirst Bank bought a new position in IDEXX Laboratories in the fourth quarter worth about $2,960,000. Finally, Pacer Advisors Inc. boosted its position in shares of IDEXX Laboratories by 10.0% during the fourth quarter. Pacer Advisors Inc. now owns 13,965 shares of the company's stock valued at $9,448,000 after purchasing an additional 1,269 shares in the last quarter. Hedge funds and other institutional investors own 87.84% of the company's stock.
Wall Street Analyst Weigh In
Several equities analysts recently commented on IDXX shares. BTIG Research cut their target price on IDEXX Laboratories from $830.00 to $800.00 and set a "buy" rating for the company in a research report on Tuesday, February 3rd. Barclays lowered their target price on IDEXX Laboratories from $850.00 to $800.00 and set an "overweight" rating for the company in a research note on Thursday, February 5th. Wall Street Zen downgraded IDEXX Laboratories from a "strong-buy" rating to a "buy" rating in a report on Saturday, February 28th. Piper Sandler dropped their price target on shares of IDEXX Laboratories from $775.00 to $750.00 and set a "neutral" rating on the stock in a research report on Monday, February 9th. Finally, UBS Group cut their price objective on shares of IDEXX Laboratories from $750.00 to $730.00 and set a "neutral" rating for the company in a research report on Tuesday, February 3rd. Seven investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $783.33.
View Our Latest Analysis on IDXX
IDEXX Laboratories Company Profile
(
Get Free Report)
IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.
IDEXX's product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
